Company Insights

ANIK customer relationships

Explore interactive graphBrowse insights index
ANIK customer relationship map

ANIK (Anika Therapeutics) — Customer network, concentration dynamics, and commercial implications

Anika Therapeutics operates as a hybrid medical-products company that manufactures, licenses, and sells osteoarthritis (OA) pain-management and regenerative solutions, monetizing through direct commercial sales, distributor channels, and long-term OEM and licensing contracts with large healthcare enterprises. The company’s economics are driven by a concentrated OEM relationship that supplies a majority of product revenue, a global distributor footprint for commercial products, and selective divestitures that rationalize non-core assets. For a focused down-stream counterparty analysis, see https://nullexposure.com/.

The one-line operating thesis investors need

Anika is a manufacturer-licensor whose near-term cash flows are dominated by its OEM/licensing partnership with Johnson & Johnson MedTech for Monovisc and Orthovisc, while its commercial channel and international distributor network provide diversification and margin capture over time. Revenue concentration with a single large partner creates both predictable volume and structural dependence; contract extensions and manufacturing investments reduce near-term headline risk but preserve a meaningful counterparty concentration profile.

How the business actually runs and what that implies

Anika’s operating model blends three revenue vectors: (1) OEM manufacturing and licensing where Anika develops and supplies product to larger partners who control sales and pricing to end users; (2) a Commercial Channel where Anika sells direct in the U.S. and through independent distributors internationally; and (3) a smaller portfolio of regenerative solutions sold to clinicians and ASCs. The company’s public filings and calls show several persistent characteristics that matter to investors:

  • Long-term contracting posture. Anika’s OEM and licensing relationships are governed by multiyear agreements that lock in supply and licensing economics while leaving end-market pricing and marketing largely with the counterparty. According to the company’s 2024 Form 10‑K, Anika entered a 15‑year licensing agreement for Monovisc in 2011 and successive extensions for Orthovisc, with the OEM channel governed by long‑term agreements (10‑K, FY2024).
  • Concentration and criticality. One large customer accounted for 57% of revenue in 2024, signaling material dependence that is central to cash-flow forecasts and pricing risk (10‑K, FY2024).
  • Global reach with North America bias. Products are sold in over 35 countries, but U.S. revenue represents the majority (about 69% of total revenue in 2024), underscoring exposure to U.S. pricing dynamics and the commercial partner’s U.S. strategy (10‑K, FY2024).
  • Mixed relationship roles. Anika acts as seller/licensor/manufacturer to OEM partners, while functioning as a commercial seller and distributor partner internationally; this split controls margin capture and risk allocation across channels (10‑K and management commentary).
  • Asset portfolio pruning. Strategic divestitures completed in 2024 simplify the company’s footprint and concentrate management attention on core OA and regenerative franchises (press releases, FY2024).

If you want a structured view of counterparties and downstream exposures, visit https://nullexposure.com/ for an expanded counterparty map.

Line‑by‑line customer and counterparty coverage

Below I cover every relationship cited in the public record for the customer scope. Each entry is a plain-English summary followed by the source.

J&J MedTech — Form 10‑K (FY2024)

J&J MedTech represented 57% of Anika’s total product revenue in 2024, down from 62% in 2023, and volume declines in the OEM channel drove an 8% revenue decrease year-over-year. According to Anika’s 2024 Form 10‑K, the company identifies J&J MedTech as its sole significant customer for product revenue (Anika 10‑K, FY2024).

Johnson & Johnson MedTech — Form 10‑K (FY2024)

In the United States, Monovisc and Orthovisc are marketed exclusively by J&J MedTech, establishing the commercial partner as the primary U.S. go‑to‑market vehicle for Anika’s flagship OA products (Anika 10‑K, FY2024).

Medacta Americas Manufacturing, Inc. — Form 10‑K (FY2024)

Anika completed the sale of Parcus Medical, LLC to Medacta Americas Manufacturing, signaling a strategic divestiture of non-core assets to streamline operations (Anika 10‑K, FY2024).

Phoenix Brio, Incorporated — Form 10‑K (FY2024)

Anika completed the sale of Arthrosurface, transferring that former subsidiary to Phoenix Brio as part of the company’s strategic portfolio reconfiguration (Anika 10‑K, FY2024).

Phoenix Brio, Incorporated — GlobeNewswire press release (Oct 31, 2024)

The sale of the Arthrosurface business closed on October 31, 2024, confirming the timing of the divestiture announced by the company (GlobeNewswire press release, Oct 31, 2024).

J&J MedTech — InsiderMonkey earnings transcript (Q4 2025 / FY2026 commentary)

Management noted that improvements in Anika’s manufacturing productivity, yield, and capacity support growth across the commercial business and the OEM partnership, and that this partnership continues to drive double‑digit Monovisc unit shipment growth (earnings transcript, Q4 2025 commentary reported by InsiderMonkey).

Johnson & Johnson — Anika earnings call (2025 Q3)

Anika management highlighted that Johnson & Johnson is taking actions to stabilize pricing in the U.S. OA pain‑management market, which accounts for the majority of Anika’s OEM channel revenue, linking partner pricing decisions directly to Anika’s near‑term top line (earnings call, 2025 Q3).

J&J MedTech — Anika earnings call (2025 Q4)

Management reiterated that manufacturing improvements directly support growth in both commercial and OEM channels and that the J&J MedTech OEM partnership continues to drive double‑digit Monovisc unit shipments, emphasizing operational leverage in production (earnings call, 2025 Q4).

Johnson & Johnson MedTech — GlobeNewswire (Nov 5, 2025)

Anika’s Q3 2025 financial release stated that the OEM channel decline was driven by lower U.S. pricing for Monovisc and Orthovisc, products sold by Johnson & Johnson MedTech, tying reported revenue weakness to partner pricing (GlobeNewswire release, Nov 5, 2025).

J&J MedTech — Anika earnings call (2025 Q3 license extension)

During the 2025 Q3 call, Anika disclosed that J&J MedTech exercised its option to extend the license and supply agreement for Monovisc for an additional five‑year term through December 2031, extending the contractual runway for that revenue stream (earnings call, 2025 Q3).

J&J MedTech — OrthospineNews coverage (July 30, 2025)

OrthospineNews reported that the revenue decline was driven by lower pricing for Monovisc and Orthovisc sold by J&J MedTech, corroborating company statements about pricing pressure in the U.S. market (OrthospineNews, July 30, 2025).

Constraints and what they mean for valuation and risk

The public constraints extracted from filings and calls present a coherent company-level signal for investors:

  • Contract maturity and structure: Multiple excerpts confirm long‑term licensing and OEM agreements, including explicit licensing terms for Monovisc and successive extensions for Orthovisc; where contracts explicitly name J&J MedTech, that relationship is a structural driver of cash flows (10‑K evidence).
  • Counterparty profile: Anika’s customers are large enterprises relative to Anika, which concentrates negotiating leverage and transfers go‑to‑market risk (company filing evidence).
  • Materiality and criticality: The designation of J&J MedTech as a single significant customer that drove 57% of revenue in 2024 is a critical signal that loss or adverse pricing by this partner would materially affect results (10‑K, FY2024).
  • Geography: The business is global in reach but North America‑weighted, so U.S. pricing dynamics and partner behavior dominate near‑term performance (10‑K geographic notes).
  • Role complexity: Anika simultaneously functions as seller, manufacturer, licensor, and distributor partner, which shapes margin dynamics—manufacturing scale benefits the OEM channel, while direct commercial sales and distributors capture higher-margin opportunities.

Investment takeaway and actions

  • Primary investment risk is counterparty concentration: One partner accounted for the majority of product revenue, albeit under long‑term agreements that were recently extended through 2031 for Monovisc. That structure provides visibility but retains dependence.
  • Operational levers reduce headline risk: Management’s emphasis on productivity, yield, and capacity expansion is a credible mechanism to support volume growth and margin improvement across channels.
  • Portfolio simplification is positive: Divestitures of Arthrosurface and Parcus reduce management distraction and sharpen capital allocation toward core OA and regenerative franchises.

For analysts and operators who need a detailed map of ANIK’s customer exposures and contract characteristics, explore the anomaly and counterparty intelligence available at https://nullexposure.com/.

Conservative underwriting of ANIK should model both (a) continued OEM volume under the extended Monovisc license through 2031, and (b) sensitivity to U.S. pricing actions by J&J MedTech. For immediate diligence and deeper counterparty breakdowns, visit https://nullexposure.com/ to review expanded relationship profiles and primary‑source links.